Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 5/20 | 0.38 |
| ▸ | CPS1 | P31327 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644128 | 0.86 | GCK (0.71) | GCKCNR1CPS1GAANPC1 | |
| SCHEMBL2644556 | 0.84 | GCK (0.69) | GCKCNR1CPS1GAAMBTD1 | |
| SCHEMBL2643863 | 0.84 | GCK (0.51) | GCKCNR1SMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL2644728 | 0.83 | GCK (0.68) | GCKCNR1CPS1GAAMBTD1 | |
| SCHEMBL644286 | 0.83 | GCK (0.81) | GCKNPC1 | |
| SCHEMBL2669284 | 0.83 | GCK (0.52) | GCKHTTCNR1CPS1SMN1; SMN2 | |
| SCHEMBL643904 | 0.81 | GCK (0.54) | GCKCNR1GAAL3MBTL1MMP2 | |
| SCHEMBL2643796 | 0.81 | GCK (0.56) | GCKHTTCNR1CPS1SMN1; SMN2 | |
| SCHEMBL2645144 | 0.80 | GCK (0.66) | GCKCPS1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL2643898 | 0.79 | GCK (0.52) | GCKCNR1SMN1; SMN2GAAMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | GCK 1/4885HTT 1560/4885CNR1 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.